A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A Study to Assess the effect of CT-868 in hemoglobin A1c (HbA1c) in Overweight and Obese Participants with Type 2 Diabetes Mellitus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Carmot Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Males or Females with T2DM

• BMI of ≥27 kg/m2, inclusive

• 18-75 years old, inclusive

• Stable body weight for 3 months

Exclusion Criteria:

• Significant medical history

• Uncontrolled diabetes

• History of malignancy